Doxorubicin: all 842 studies that test it
Page 5 of 9. Open to participants first (91), then studies with results posted, then the rest; newest registration first within each.
- Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue SarcomaStatus unknownNCT03880695Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
- Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian CancerStatus unknownNCT03794778Phase 4
- Radical Resection and HIPEC for Recurrent Retroperitoneal SarcomaActive, not recruitingNCT03792867Not applicable
- APX005M and Doxorubicin in Advanced SarcomaCompletedNCT03719430Phase 2
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedNCT03719326Phase 1
- CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCERActive, not recruitingNCT03712956Phase 2
- OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma PatientsTerminatedNCT03698227Phase 2
- A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.CompletedNCT03681548Phase 1
- Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedNCT03639246Phase 1
- Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian CancerCompletedNCT03596281Phase 1
- Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaWithdrawnNCT03591744Phase 1
- Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney CancerCompletedNCT03587662Phase 2
- RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis FactorCompletedNCT03536039Phase 2
- Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer PatientsStatus unknownNCT03509246Phase 2
- Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent LeiomyosarcomaWithdrawnNCT03437070Phase 1
- Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingStatus unknownNCT03412643Phase 2
- PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid CarcinomaStatus unknownNCT03387943Phase 2
- TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid TumorsTerminatedNCT03387917Phase 1
- Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast CancerStatus unknownNCT03359694Phase 3
- Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue SarcomaWithdrawnNCT03342300Phase 2/3
- Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerActive, not recruitingNCT03340376Phase 2
- Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian CancerStatus unknownNCT03335241Phase 2
- MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast CancerWithdrawnNCT03285607Phase 1
- Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast CancerCompletedNCT03221881Not applicable
- Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and AdolescentsActive, not recruitingNCT03206671Phase 3
- Risk Adapted Therapy in Diffuse Large B Cell LymphomaStatus unknownNCT03188198Phase 2
- FIL Study on ABVD DD-DI as Upfront Therapy in HL.CompletedNCT03159897Phase 3
- Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer PatientsStatus unknownNCT03123770Phase 4
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in ChildrenWithdrawnNCT03111069Phase 1
- Metronomic PLD in Patients With Primary Endocrine Resistant ABCStatus unknownNCT03071926Phase 2
- A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDSWithdrawnNCT03059615Phase 2
- Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue SarcomaCompletedNCT03056599Phase 1
- Study of Selinexor and Doxorubicin in Advanced Soft Tissue SarcomasCompletedNCT03042819Phase 1
- Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous TumorCompletedNCT03023124Phase 2
- A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast CancerCompletedNCT03017404Not applicable
- Paediatric Hepatic International Tumour TrialActive, not recruitingNCT03017326Phase 3
- Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by SurgeryCompletedNCT03009201Phase 1
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer PatientsCompletedNCT03000036Not applicable
- Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant ChemotherapyStatus unknownNCT02953184Phase 2
- L-DEP as an Initial Treatment for EBV-HLHStatus unknownNCT02912702Phase 3
- Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast CancerStatus unknownNCT02903524Phase 4
- Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 StudyStatus unknownNCT02894645Phase 4
- Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant GliomaCompletedNCT02861222Phase 1
- EDOCH Alternating With DHAP for New Diagnosed Younger MCLCompletedNCT02858804Phase 4
- LBL-2016 for Children or Adolescents in ChinaActive, not recruitingNCT02845882Phase 3
- DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast CancerCompletedNCT02838225Phase 2
- Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma TreatmentStatus unknownNCT02812654Phase 2
- Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and OverStatus unknownNCT02792491Phase 2
- Response Based Treatment for Children With Unresectable Localized Soft Tissue SarcomaStatus unknownNCT02784015Phase 2
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedNCT02779283Phase 1
- Response-based Treatment of High-risk NeuroblastomaStatus unknownNCT02771743Phase 2
- Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine GliomaTerminatedNCT02758366Phase 2
- Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant CancerCompletedNCT02751918Phase 1
- Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.TerminatedNCT02670317Phase 2
- Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi SarcomaActive, not recruitingNCT02659930Phase 1
- L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic LymphohistiocytosisStatus unknownNCT02631109Phase 3
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
- Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of RetroperitoneumStatus unknownNCT02587169Phase 1/2
- Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)Active, not recruitingNCT02584478Phase 3
- HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid TumorsWithdrawnNCT02557854Phase 1
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnNCT02538926Phase 2
- Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular CarcinomaWithdrawnNCT02527772Phase 2/3
- Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) PatientsActive, not recruitingNCT02499367Phase 2
- A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast CancerCompletedNCT02488564Phase 2
- Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma PatientsCompletedNCT02471820Phase 2
- Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCLStatus unknownNCT02445404Phase 2
- R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell LymphomaStatus unknownNCT02428751Phase 3
- Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02420847Phase 1/2
- Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and DoxorubicinCompletedNCT02414568Phase 2
- Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin LymphomaStatus unknownNCT02275598Phase 2
- Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid TumorsCompletedNCT02262455Phase 1
- Bioequivalence Study of Doxorubicin Hydrochloride Liposome InjectionCompletedNCT02260544Phase 1
- Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian CancerCompletedNCT02237690Phase 1
- Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerWithdrawnNCT02215876Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk NeuroblastomaActive, not recruitingNCT02176967Phase 3
- A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast CancerTerminatedNCT02131506Phase 1
- Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic LeiomyosarcomaCompletedNCT02131480Phase 2
- Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable PatientsStatus unknownNCT02099188Phase 2
- Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable PatientsStatus unknownNCT02099175Phase 2
- A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian CancerCompletedNCT02081495Phase 1
- L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid TumoursCompletedNCT02076620Phase 1
- PREDATOR: Neoadjuvant Gene Prediction for Breast CancerWithdrawnNCT02067416Phase 2
- Efficacy of Dose Intensification in Patients With Non-metastatic Ewing SarcomaCompletedNCT02063022Phase 3
- TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free RegimenWithdrawnNCT02053597Phase 2
- Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal CancerActive, not recruitingNCT01970722Phase 1
- Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast CancerCompletedNCT01969032Phase 2
- TACE as an Adjuvant Therapy After Hepatectomy for HCCStatus unknownNCT01966133Phase 3
- 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast CancerCompletedNCT01935492Phase 3
- A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial CancerCompletedNCT01918124Phase 2
- Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT01902225Phase 1
- Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer PatientsCompletedNCT01885013Phase 2
- Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified ChemotherapyActive, not recruitingNCT01871766Phase 2
- Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm PatientStatus unknownNCT01858207Phase 2
- Intraperitoneal Aerosol Chemotherapy in Gastric CancerCompletedNCT01854255Phase 2